Mosaic TX
United Kingdom
- Hinxton, Cambridgeshire
- 05/04/2023
- Series A
- $28,000,000
ABOUT US
Mosaic Therapeutics is an oncology therapeutics company using advanced computational methods and next-generation cancer models to discover and develop novel targeted therapies. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery.
Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active programmes across a variety of oncology indications and disease biology pathways
- Industry Biotechnology
- Website https://www.mosaic-tx.com/
- LinkedIn https://www.linkedin.com/company/mosaic-tx/
Related People
Brian GladsdenFounder
United Kingdom -
ND
An inspiring, purpose-driven leader, unleashing the power of science and people to improve human health.
Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)